Update: ACIP 2024 Adult Immunization Recommendations

Feature
Slideshow

This summary of updates to the ACIP 2024 Adult Vaccination recommendations includes 4 new vaccines and new formulations for COVID-19 and influenza shots.

This summary of the Advisory Committee on Immunization Practices 2024 Adult Immunization Schedule,1 approved and released by the Centers for Disease Control and Prevention in January 2024, highlights 4 new vaccines, new recommendations,2 and subsequent developments that include new COVID-19 vaccine targeted strain and updated RSV vaccine recommendations.

References
1. Centers for Disease Control and Prevention, US Department of Health and Human Services. Recommended Adult Immunization Schedule2024. Accessed July 15, 2024. https://www.cdc.gov/vaccines/schedules/hcp/imz/adult.html
2. Advisory Committee on Immunization Practices (ACIP). ACIP Recommendations. June 28, 2024. Accessed July 15, 2024. https://www.cdc.gov/vaccines/acip/recommendations.html

Recent Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
Moderna's mRNA-1010 Influenza Vaccine Proves Superior Efficacy in Pivotal Late-Stage Trial / image credit ©digitalskillet1/stock.adobe.com

Moderna's mRNA-1010 Flu Vaccine Proves Superior Efficacy in Pivotal Late-Stage Trial

Grace Halsey
June 30th 2025
Article

The vaccine showed superior relative vaccine efficacy that was 26.6% higher than a licensed standard-dose influenza vaccine, Moderna reported.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Keith A. Reynolds
October 1st 2024
Podcast

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Moderna Announces Withdrawal of BLA for Flu/COVID-19 Combination Vaccine / image credit ©desertsands/stock.adobe.com

Moderna Announces Withdrawal of BLA for Flu/COVID-19 Combination Vaccine

Grace Halsey
May 22nd 2025
Article

Moderna voluntarily withdrew the BLA after consultation with the FDA and will resubmit once it has additional phase 3 efficacy data for its investigational flu shot.

Single Dose of Arexvy RSV Vaccine Shows 3-Year Protection in Older Adults: Daily Dose / image credit: ©New Africa/AdobeStock

Single Dose of Arexvy RSV Vaccine Shows 3-Year Protection in Older Adults: Daily Dose

Sydney Jennings
May 20th 2025
Article

Your daily dose of the clinical news you may have missed.

FDA grants Novavax COVID-19 vaccine full approval for high risk groups / image credit ©Waldenmarus/stock.adobe.com

FDA Grants Novavax COVID-19 Vaccine Full Approval for High-Risk Groups

Grace Halsey
May 20th 2025
Article

Nuvaxovid (NVX-CoV2373) is indicated for those aged ≥65 years and aged 12 to 64 years with at least one condition that puts them at high risk for severe infection.

Novavax JN.1 COVID-19 Vaccine Linked to Fewer Side Effects Than mRNA in Health Care Workers

Novavax JN.1 COVID-19 Vaccine Linked to Fewer Side Effects Than mRNA in Health Care Workers

Sydney Jennings
April 22nd 2025
Article

Novavax’s COVID-19 vaccine was linked to fewer and less severe side effects vs mRNA in a University of Utah study of health care workers.

© 2025 MJH Life Sciences

All rights reserved.